Up to 70% of thrombotic patients with no identifiable risk factors were termed idiopathic. Now, molecular diagnostics combined with existing laboratory techniques allow accurate classification of at least half of patients with inherited thrombotic disorders. However, the previously studied genetic variants explain only a fraction of all thromboembolic events, so the aim of the present study was to expand the genetic prevalence determination to include also more extensive thrombophilic gene polymorphisms in patients with DVT compared to healthy subjects in Egyptian population. This study was conducted on 75 patients with DVT and 45 age and sex matched healthy subjects as control group. The diagnosis of DVT was based on patient's history, clinical findings, D-dimer test, and confirmed by Doppler ultrasonography. Both groups were assessed for thrombophilic gene polymorphisms using multiplex polymerase chain reaction and reverse-hybridization technique through CVD strip assay. It was found that FV Leiden G1691A (P=0.001), Factor V H1299R (P=0.02), MTHFR A1298C (P=0.02), β-fibrinogen−455 G/A (P=0.01), PAI-1 4G/5G (P=0.03) and ACE (P=0.03) polymorphisms were all significantly associated with an increased risk of DVT. Our data are of extreme importance in clinical practice for introducing the extended CVD panel into routine molecular diagnostic tests to allow management of thrombotic patients and screening, thromboprophylaxis and genetic counselling for high-risk individuals.
INTRODUCTION
Venous thromboembolism (VTE) represents a major health problem worldwide and has a high incidence in several populations across the world 
MATERIAL AND METHODS
A total of 75 individuals with DVT clinical symptoms were enrolled in this study as a patient group, and 45 healthy subjects without both personal and family histories of thromboembolic disorders were included as a control group. All case subjects were referred to cardiology department of Benha University hospitals, Benha, The CVD Strip Assay (ViennaLab, Labordiagnostika GmbH, Vienna, Austria) was used to detect the previously described polymorphisms of genes according to the manufacturer's protocol.
Briefly, the procedure included three steps: DNA isolation, PCR amplification, and hybridization of amplification products as follows: 
Interpretation of genotyping results
For each polymorphic position, one of three 
RESULTS
The demographic data of the study subjects are presented in Table ( andHPA-1 in the sample of Egyptian population studied; either normal subjects or DVT patients. Therefore, this study tried to expand molecular analysis to include a more extensive genetic thrombophilia profiling which was not evaluated before in Egyptian population with DVT, through using CVD StripAssay, which covers 12 polymorphisms.
According to our studied population, the incidence of DVT was about 2 fold higher in females than in males, a finding consistent with a previous study on Iranian population which reported that the prevalence of DVT was more in females [36] . Moreover, in a study on Croatian population FV Leiden was found to be the highest most frequent thrombophilia gene polymorphism out of 4 gene polymorphisms studied including factor II G20210A, FV Leiden, MTHFR C677T and PAI-1 5G/4G polymorphisms [42] . Conversely, there were previous studies, that failed to determine the contributory role of FV Leiden on the DVT occurrence in Iranian population [43, 44] .
In this study, there was an association between Factor V H1299R (also known as HR2) and DVT.
Consistent with our data, Bouaziz-Borgi et al.
(2007) [45] found that this polymorphism had a possible role in VTE. In addition, Gohil et al. As regards PTH G20210A polymorphism, it was previously found that it leads to increased messenger RNA and protein expression [51] . High PTH plasma levels may act through an increase in endogenous thrombin potential, a key step in hemostasis and thrombosis [52] . Moreover, increased PTH levels may lead to an increase in the inhibitor of fibrinolysis; thrombin-activatable fibrinolysis inhibitor, that disturbs the fibrinolysis process and thus may add to the hypercoagulable status in these patients [53, 54] . In accordance with PAI-1, a member of the serine protease inhibitor (serpine) super family, is the main regulator for the endogenous fibrinolytic system and is the principle inhibitor of t-PA and u-PA in the fibrinolytic system [61] . It modulates the thrombosis progression [62] . Elevated levels of PAI-1 are associated with venous thrombosis [63] .
This study showed that there was a significant This accordingly increases the risk of atherosclerosis and hypercholesterolemia [73] .
ApoB-100 R3500Q polymorphism; a single nucleotide transition, CGG to CAG, in exon 26, reduces the affinity to the LDL receptor by at least 95% and is the major cause of familial defective ApoB-100 (FDB). Because the cholesterol concentration is often within the reference interval in FDB patients, the only reliable way of detecting FDB is by genotyping [74] . [76] reported that the genotype frequencies of E3/E3, E2/E3 and E3/E4 were 68.75%, 13.75% and 16.25% respectively, and the E2/E4 and E4/E4
were only found in 0.625% of the population.
Overall, according to our results, FV G1691A, 
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